EVO | Evotec SE Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.10 - 4.16
52 Week Range	2.8500 - 8.39
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	36,847
Average Volume	237,185
Shares Outstanding	354,606,170
Market Cap	1,464,523,482
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2004-02-05

Valuation
Profitability
Growth
Health
P/E Ratio	-8.26
Forward P/E Ratio	N/A
EPS	-0.50
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	5,007
Country	Germany
Website	EVO

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

EVO's peers: AMPH, PBH, SUPN, COLL, DCPH, EGRX, ANIP, PAHC, PCRX, RDY, SSIC, RGC, NBIX, TAK

*Chart delayed

Analyzing fundamentals for EVO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is good and Health is frighteningly weak. For more detailed analysis please see EVO Fundamentals page.

Watching at EVO technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on EVO Technicals page.